BCL2 and cancer: In addition to ABT-199 and ABT-263, other Bcl-2 family inhibitors have been evaluated in clinical trials for cancer treatment [71], including molecules targeting MCL-1 (A-1210477, S63845, AMG 176, AZD5991) [72,73,74,75].